Subscribe
handshake-1
miodrag ignjatovic / iStockphoto.com
10 May 2018Asia-Pacific

AstraZeneca sells Seroquel rights for $538m

AstraZeneca has agreed to sell its rights to Seroquel (quetiapine fumarate) and Seroquel XR to China-based pharmaceutical company Luye Pharma Group for $538 million.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Will Big Pharma get the bug for microbiome therapies?
6 May 2020   The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Americas
AstraZeneca sells US rights to four drugs for $46.5m
3 January 2018   AstraZeneca has sold the US rights and New Drug Applications to four drugs to ANI Pharmaceuticals, a speciality pharmaceutical company.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
Will Big Pharma get the bug for microbiome therapies?
6 May 2020   The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Americas
AstraZeneca sells US rights to four drugs for $46.5m
3 January 2018   AstraZeneca has sold the US rights and New Drug Applications to four drugs to ANI Pharmaceuticals, a speciality pharmaceutical company.

More on this story

Big Pharma
Will Big Pharma get the bug for microbiome therapies?
6 May 2020   The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Americas
AstraZeneca sells US rights to four drugs for $46.5m
3 January 2018   AstraZeneca has sold the US rights and New Drug Applications to four drugs to ANI Pharmaceuticals, a speciality pharmaceutical company.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler